> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – September 2012

Loading EJC News Focus video

Genetics meet therapeutics at EACR-22

The influence of genetics on patient treatments was explored and expanded on in different presentations at the recent 22nd EACR Biennial Congress (Barcelona, Spain; 7-10th July). Next generation sequencing is leading to the development of new therapeutic agents; clinical trials are documenting patients’ responses to those therapies and then feeding back into experimental work.

Richard Marais (Director of the Paterson Institute, Manchester, UK) is EACR’s Secretary-General and a member of EJC’s Editorial Board. In this month’s EJC News Focus, he outlines the main themes of the Congress.